Krystal Biotech reports positive ocular data from compassionate use of B-VEC in DEB patient

Krystal Biotech, Inc.

Topical B-VEC achieved full corneal healing by 3 months and improved visual acuity from hand motion to 20/40 at 7 months.
No drug-related adverse events observed; treatment was well tolerated in the patient.
Patient had recurrent cicatrizing conjunctivitis; ocular complications affect >50% of recessive DEB patients.
Company plans to engage regulators to expand B-VEC utility for ocular DEB manifestations.
Ongoing preclinical studies evaluating intravitreal and subretinal deliveries for other ocular diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.